Truist Financial Increases Humana (NYSE:HUM) Price Target to $290.00

Humana (NYSE:HUM) had its price target raised by equities researchers at Truist Financial from $260.00 to $290.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “hold” rating on the insurance provider’s stock. Truist Financial’s target price points to a potential upside of 8.71% from the stock’s current price.

Several other equities research analysts have also recently issued reports on HUM. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a research note on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft cut their price objective on Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and upped their target price for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Stephens reissued an “equal weight” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Finally, UBS Group decreased their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a report on Friday, October 4th. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $302.00.

Humana Stock Up 0.9 %

NYSE HUM opened at $266.77 on Monday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 52 week low of $213.31 and a 52 week high of $464.38. The business’s fifty day simple moving average is $272.82 and its 200-day simple moving average is $312.17. The firm has a market cap of $32.12 billion, a PE ratio of 23.63, a P/E/G ratio of 2.12 and a beta of 0.55.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. As a group, equities analysts anticipate that Humana will post 16.14 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Trading of Humana

Institutional investors have recently modified their holdings of the stock. Creative Financial Designs Inc. ADV raised its stake in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new position in shares of Humana during the third quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new stake in shares of Humana during the third quarter worth about $31,000. Your Advocates Ltd. LLP lifted its holdings in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Finally, Hollencrest Capital Management acquired a new stake in shares of Humana in the 2nd quarter valued at about $40,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.